Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance
Meena Murali(Amrita Vishwa Vidyapeetham), Lekshmi R. Nath(Rajiv Gandhi Centre for Biotechnology), Bhagyalakshmi Nair(Amrita Institute of Medical Sciences and Research Centre), Aswathy R. Devan(Amrita Vishwa Vidyapeetham), Goriparthi Pradeep(Amrita Vishwa Vidyapeetham), Ayana R. Kumar(Amrita Vishwa Vidyapeetham), K Pavithran(Amrita Institute of Medical Sciences and Research Centre)
Cited by 17
Related Papers
Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets
|Molecular Biology Reports|2021|148
Inevitable role of TGF-β1 in progression of nonalcoholic fatty liver disease
|Journal of Receptors and Signal Transduction|2020|74
Evaluation of uttroside B, a saponin from Solanum nigrum Linn, as a promising chemotherapeutic agent against hepatocellular carcinoma
|Scientific Reports|2016|57
Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review
|Journal of Food Biochemistry|2021|50
The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential
|European journal of medical research|2024|40